Vimarsana
Biggest News Aggregation in the World

Page 13 - Adaptive Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adaptive Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adaptive Research Today - Breaking & Trending Today

Pfizer Drops a Cool $11.6B on Migraine Leader Biohaven - Vimarsana News

Pfizer Drops a Cool $11.6B on Migraine Leader Biohaven

Pfizer made the splash of the young week Tuesday morning, inking an acquisition deal with New Haven, Connecticut-based Biohaven Pharma totaling $11.6 billion.

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial | Critical Care Medicine | JAMA - Vimarsana News

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial | Critical Care Medicine | JAMA

This randomized clinical trial assesses the effect of treatment with an antiplatelet agent vs no antiplatelet therapy on days alive and free of intensive care u

BioSpace Movers & Shakers: Enveda, Evaxion, Elevation - Vimarsana News

BioSpace Movers & Shakers: Enveda, Evaxion, Elevation

Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.

Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update - Vimarsana News

Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma - Vimarsana News

Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma

/PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced its lead candidate VT1021 will...